Olema Pharmaceuticals, Inc. (OLMA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

512 2ND STREET, 4TH FLOOR SAN FRANCISCO, CA 94107

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist, and a selective ER degrader (SERD). OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase4 (CDK4)/6 demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.

Data as of 2021-08-02 09:18:52 -0400
Market Cap943.185 Million Shares Outstanding40.17 Million Avg 30-day Volume210.675 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE23.48 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low60.27 / 19.41 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -73.2697
Data provided by IEX Cloud
View SEC Filings from OLMA instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 4 6 -33.33% 3 (0.18%) 5 (0.29%) -40.0%
Funds Holding: 74 58 27.59% 26 (1.53%) 24 (1.39%) 8.33%
13F shares: 35.237 Million 35.074 Million 0.46% 25.431 Million 25.881 Million -1.74%
% Ownership 87.7198 87.3142 0.46% 63.3078 64.4285 -1.74%
New Positions: 32 57 -43.86% 8 24 -66.67%
Increased Positions 15 5
Closed Positions 16 6
Reduced Positions 13 4
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Olema Pharmaceuticals, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding OLMA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OLMA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

34.5 Thousand total shares from 10 transactions

Exercise Derivative Conversion (M)

10.5 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

1,209,574 2021-07-20 4

HORN KINNEY CHIEF BUSINESS OFFICER

185,585 2021-07-12 5

GRAHAM G. WALMSLEY

21,520 2021-06-09 3

HRUSTANOVIC GORJAN

21,520 2021-06-09 3

HORNING SANDRA

21,520 2021-06-09 3

CLARK IAN T

21,520 2021-06-09 3

BUTITTA CYNTHIA M

21,520 2021-06-09 3

RAPPAPORT ANDREW

21,520 2021-06-09 4

LARSON YI

21,520 2021-06-09 3

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • Director
  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
6,516,126 2021-03-31 1

BOHEN SEAN PRESIDENT AND CEO

  • Officer
  • Director
 75,000 2021-03-15 3

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

CORMORANT PRIVATE HEALTHCARE FUND II, LP

CORMORANT PRIVATE HEALTHCARE FUND III LP

  • Director
  • 10% Owner
  • FORMER 10% OWNER
No longer subject to file 2020-11-23 1

MYLES DAVID C. CHIEF DEVELOPMENT OFFICER

  • Officer
 759,498 2020-11-23 2

MCCORMICK FRANK

  • Director
 275,373 2020-11-23 3

KUSHNER PETER J. CHIEF SCIENTIFIC OFFICER

  • Officer
 1,431,672 2020-11-23 2

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
 No longer subject to file 2020-11-23 2

MORIARTY JOHN B EVP, CH. LEGAL OFFICER & SEC.

  • Officer
 0 2020-11-18 2

KOVACS SHANE WILLIAM CHARLES CH. OPERATING & FINANCIAL OFF.

  • Officer
 358,680 2020-11-18 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

2021-07-21 17:29:39 -0400 2021-07-20 S 4,123 $25.63 d 1,087,546 direct yes 3.6532 -5.5801 3.6532 2 -7.8282 4

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

2021-07-21 17:29:39 -0400 2021-07-19 S 7,877 $24.83 d 1,091,669 direct yes 3.6532 -5.5801 3.6532 2 -7.8282 4

HORN KINNEY CHIEF BUSINESS OFFICER

2021-07-13 18:27:00 -0400 2021-07-12 S 1,392 $27.00 d 1,790 direct yes 2.4691 8.0247 8.0247 6 0.0 1

HORN KINNEY CHIEF BUSINESS OFFICER

2021-07-13 18:27:00 -0400 2021-07-12 S 3,859 $26.33 d 3,182 direct yes 2.4691 8.0247 8.0247 6 0.0 1

HORN KINNEY CHIEF BUSINESS OFFICER

2021-07-13 18:27:00 -0400 2021-07-12 M 5,251 d 183,795 direct

HORN KINNEY CHIEF BUSINESS OFFICER

2021-07-13 18:27:00 -0400 2021-07-12 M 5,251 $2.06 a 7,041 direct 2.4691 8.0247 8.0247 6 0.0 1

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

2021-06-21 19:05:36 -0400 2021-06-18 S 600 $26.30 d 1,099,546 direct yes 1.9128 7.039 14.9962 4 0.0 1

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

2021-06-21 19:05:36 -0400 2021-06-18 S 1,990 $25.59 d 1,100,146 direct yes 1.9128 7.039 14.9962 4 0.0 1

HARMON CYRUS CHIEF TECHNOLOGY OFFICER

2021-06-21 19:05:36 -0400 2021-06-18 S 9,410 $24.54 d 1,102,136 direct yes 1.9128 7.039 14.9962 4 0.0 1

HORN KINNEY CHIEF BUSINESS OFFICER

2021-06-11 16:30:07 -0400 2021-06-10 M 5,251 d 189,046 direct

HORN KINNEY CHIEF BUSINESS OFFICER

2021-06-11 16:30:07 -0400 2021-06-10 S 300 $28.30 d 6,741 direct yes 2.006 -15.112 -23.2364 2.006 2 -23.2364 31

HORN KINNEY CHIEF BUSINESS OFFICER

2021-06-11 16:30:07 -0400 2021-06-10 S 2,787 $29.97 d 1,790 direct yes 2.006 -15.112 -23.2364 2.006 2 -23.2364 31

HORN KINNEY CHIEF BUSINESS OFFICER

2021-06-11 16:30:07 -0400 2021-06-10 M 5,251 $2.06 a 7,041 direct 2.006 -15.112 -23.2364 2.006 2 -23.2364 31

HORN KINNEY CHIEF BUSINESS OFFICER

2021-06-11 16:30:07 -0400 2021-06-10 S 2,164 $29.60 d 4,577 direct yes 2.006 -15.112 -23.2364 2.006 2 -23.2364 31

BUTITTA CYNTHIA M

2021-06-10 18:36:51 -0400 2021-06-09 A 21,520 a 21,520 direct

CLARK IAN T

2021-06-10 18:40:23 -0400 2021-06-09 A 21,520 a 21,520 direct

RAPPAPORT ANDREW

2021-06-10 18:35:22 -0400 2021-06-09 A 21,520 a 21,520 direct

GRAHAM G. WALMSLEY

2021-06-10 18:38:13 -0400 2021-06-09 A 21,520 a 21,520 direct

LARSON YI

2021-06-10 18:36:13 -0400 2021-06-09 A 21,520 a 21,520 direct

HRUSTANOVIC GORJAN

2021-06-10 18:43:00 -0400 2021-06-09 A 21,520 a 21,520 direct

HORNING SANDRA

2021-06-10 18:39:20 -0400 2021-06-09 A 21,520 a 21,520 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
OLEMA PHARMACEUTICALS INC OLMA 2021-08-03 13:15:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-03 12:45:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 22:15:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 21:45:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 21:15:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 20:45:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 20:15:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 19:45:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 19:15:03 UTC -1.33 1.39 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 18:45:03 UTC -1.3368 1.3968 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 18:15:03 UTC -1.3368 1.3968 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 17:45:03 UTC -1.3368 1.3968 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 17:15:03 UTC -1.3368 1.3968 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 16:45:03 UTC -1.3387 1.4187 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 16:15:03 UTC -1.3387 1.4187 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 15:45:03 UTC -1.3387 1.4187 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 15:15:03 UTC -1.3387 1.4187 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 14:45:03 UTC -1.3059 1.3859 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 14:15:03 UTC -1.3059 1.3859 450000
OLEMA PHARMACEUTICALS INC OLMA 2021-08-02 13:45:03 UTC -1.3059 1.3859 450000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments